Relapsed Hodgkin Lymphoma
Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
M&
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
ADC TherapeuticsCamidanlumab Tesirine
Merck & Co.Pembrolizumab
Clinical Trials (2)
Total enrollment: 6 patients across 2 trials
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Start: Sep 2019Est. completion: Jan 2023
Phase 2Completed
Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
Start: Aug 2016Est. completion: Oct 20176 patients
Phase 1/2Terminated
Related Jobs in Oncology
Cell Therapy Account Manager（北陸）
Gilead Sciences
Japan - Tokyo
Just now
Leo Cancer Care: Senior In-House Counsel/General Counsel
Leo Cancer Care
Middleton, Wisconsin
5h ago
Summer Intern - Computational Chemistry & Artificial Intelligence
Arvinas
Remote
7h ago
Executive Medical Director, Oncology Early Development
AbbVie
Florham Park, NJ
8h ago
Executive Medical Director, Oncology Early Development
AbbVie
South San Francisco, CA
8h ago
Executive Medical Director, Oncology Early Development
AbbVie
North Chicago, IL
8h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Monoclonal Antibody is the dominant modality (100% of programs)
2 companies competing in this space